Description

Mefarmil (Metformin Hydrochloride) Coated Tablets 850 mg. №30

Ingredients

Active ingredient: Metformin hydrochloride 850 mg.

Dosage

Dosage: The usual starting dose is 500 mg or 850 mg once daily with meals. Dosage adjustments should be made based on blood glucose levels.

Indications

Indications: Mefarmil tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Contraindications

Contraindications: Do not use Mefarmil in patients with renal impairment, acute or chronic metabolic acidosis, or hypersensitivity to metformin.

Directions

Directions: Swallow the tablets whole with a full glass of water. Follow the dosage instructions provided by your healthcare provider.

Scientific Evidence

Metformin, the active ingredient in Mefarmil, is a first-line medication for the treatment of type 2 diabetes. It works by decreasing glucose production in the liver and improving insulin sensitivity in the muscles. Several studies have demonstrated the efficacy of metformin in lowering blood sugar levels and reducing the risk of diabetes-related complications.

Additional Information

Mefarmil coated tablets 850 mg are formulated for sustained release, providing long-lasting glycemic control throughout the day. It is important to monitor blood glucose levels regularly while taking this medication to ensure optimal efficacy and safety.

Pharmacological Effects: Metformin acts by increasing the uptake and utilization of glucose by peripheral tissues and decreasing glucose absorption in the gastrointestinal tract. It also has beneficial effects on lipid metabolism and may contribute to weight loss in some patients.

Clinical Trials: Clinical trials have shown that metformin not only improves glycemic control but also reduces the risk of cardiovascular events in patients with type 2 diabetes. A study published in the New England Journal of Medicine found that metformin therapy was associated with a significant reduction in the incidence of major cardiovascular events compared to placebo.